Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides
US9206239B2 · kind B2 · utility
0Cited by
42References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 19, 2013 |
| Grant date | Dec 8, 2015 |
| Priority date | — |
| Expiry date | Aug 19, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16322
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.